A little clarity for your next chapter.
Show the work

The sources
behind the words.

Primary provider pages for service information. Regulators, guidelines, and human research for the medical context. Each article links the sources it uses.

Provider primary source

CoreAge Rx: Sermorelin product page

Live product page; starting price is not a verified checkout total.

Provider help center

CoreAge Rx: About the service

The page discusses GLP-1 services; do not automatically apply those billing terms to sermorelin.

Provider primary source

AgelessRx: Sermorelin Injection

Product page includes introductory and recurring price language; check the selected plan.

Provider primary source

AgelessRx: Sermorelin Nasal Spray

Different delivery route; injectable evidence is not proof of equivalent nasal outcomes.

Provider primary source

IVY RX: Sermorelin Injections

Live retrieval showed a $179 starting figure with use varying; other indexed versions differed.

Provider pricing article

IVY RX: Sermorelin cost guide

Plan examples can differ from the current product page; not a checkout quote.

Provider primary source

Hone Health: Sermorelin Injections

Medication and membership figures are displayed separately.

Provider primary source

Strut Health: Injectable Sermorelin Peptide Therapy

Auto-refill starting price; confirm quantity, interval, and total before paying.

Provider patient document

Defy Medical: Sermorelin patient handout

Historical vial pricing and pharmacy names; current availability and care fees require confirmation.

Provider educational and commercial page

Invigor Medical: Sermorelin studies and offering

Public article advertises treatment; current checkout and total costs were not tested.

Provider help center

Invigor Medical: Sermorelin FAQs

Some broad outcome claims go beyond what the evidence establishes.

US regulator

FDA: Risks of compounded drugs

Explains lack of FDA approval and the risks of poor-quality compounded preparations.

US regulator

FDA: Compounding questions and answers

Compounded medicines differ from FDA-approved generic drugs.

Federal Register / FDA

FDA: 2013 GEREF withdrawal determination

Historical GEREF products were not withdrawn for safety or effectiveness reasons; this does not approve current compounds.

Clinical practice guideline

Endocrine Society: Adult growth hormone deficiency

Diagnosis and treatment of established deficiency; not an endorsement of anti-aging prescribing.

Expert clinical evidence review

Endotext: Growth Hormone and Aging

Separates hormone and body-composition findings from functional outcomes and long-term unknowns.

Human controlled study, 2006

Vitiello et al.: GHRH and cognition in older adults

A six-month study in 89 older adults; not evidence of dementia prevention or all current preparations.

US government guidance

HHS: Telehealth licensing across state lines

Licensure options depend on the patient location and state rules.

Medical board directory

FSMB: Contact a state medical board

Find the relevant state authority to verify a physician.

Pharmacy regulator association

NABP: Buy medication safely

Tools for checking online pharmacies and recognizing unsafe sellers.

Federal geographic dataset

US Census Bureau: 2025 Gazetteer places

Incorporated places and census-designated places; not a list of clinics or every neighborhood.

US regulator

FDA: Safely using sharps at home

Sharps handling and disposal; local collection rules vary.

US National Library of Medicine

MedlinePlus: Sleep disorders

General sleep disorder education; not a sermorelin efficacy source.

US National Library of Medicine

MedlinePlus: Fatigue

Fatigue has many causes that may need evaluation.

Provider primary source

MaleMD: Doctor-prescribed sermorelin

Checked September 20, 2026. Advertised offering only; checkout, patient suitability, and dispensing were not tested.

Provider primary source

Everlife: Sermorelin GHK

Checked September 20, 2026. Advertised offering only; checkout, patient suitability, and dispensing were not tested.

Provider primary source

Eden: Sermorelin injection

Checked September 20, 2026. Advertised offering only; checkout, patient suitability, and dispensing were not tested.

Provider primary source

Eden: Sermorelin ODT

Checked September 20, 2026. Advertised offering only; checkout, patient suitability, and dispensing were not tested.

Provider primary source

ReadyRx: Sermorelin

Checked September 20, 2026. Advertised offering only; checkout, patient suitability, and dispensing were not tested.

Provider primary source

ReadyRx: Sermorelin ODT

Checked September 20, 2026. Advertised offering only; checkout, patient suitability, and dispensing were not tested.

Provider primary source

Healthon: Sermorelin injection

Checked September 20, 2026. Advertised offering only; checkout, patient suitability, and dispensing were not tested.

Provider primary source

Healthon: Sermorelin ODT

Checked September 20, 2026. Advertised offering only; checkout, patient suitability, and dispensing were not tested.

Provider primary source

bmiMD: Sermorelin injection

Checked September 20, 2026. Advertised offering only; checkout, patient suitability, and dispensing were not tested.

Provider primary source

Olympia Pharmacy: Compounded sermorelin injection

Checked September 20, 2026. Advertised offering only; checkout, patient suitability, and dispensing were not tested.

Provider primary source

Maximus: Sermorelin and aging

Checked September 20, 2026. Advertised offering only; checkout, patient suitability, and dispensing were not tested.

Provider primary source

Embody Her Health: Sermorelin

Checked September 20, 2026. Advertised offering only; checkout, patient suitability, and dispensing were not tested.

Clinical or regulatory reference

Mayo Clinic: Sermorelin injection information

Checked September 20, 2026. Findings apply to the specified molecule, route, and population.

Clinical or regulatory reference

FDA: Bulk drug substances under section 503A

Checked September 20, 2026. Findings apply to the specified molecule, route, and population.

Clinical or regulatory reference

FDA: Peptide compounding safety concerns

Checked September 20, 2026. Findings apply to the specified molecule, route, and population.

Clinical or regulatory reference

DailyMed: EGRIFTA WR prescribing information

Checked September 20, 2026. Findings apply to the specified molecule, route, and population.

Clinical or regulatory reference

NIDDK: Prescription medications for weight management

Checked September 20, 2026. Findings apply to the specified molecule, route, and population.

Clinical or regulatory reference

Endocrine Society: Testosterone therapy guideline

Checked September 20, 2026. Findings apply to the specified molecule, route, and population.

Clinical or regulatory reference

Sigalos and Pastuszak: Safety and efficacy of growth hormone secretagogues

Checked September 20, 2026. Findings apply to the specified molecule, route, and population.

Clinical or regulatory reference

Sinha et al.: Growth hormone secretagogues and male body composition

Checked September 20, 2026. Findings apply to the specified molecule, route, and population.

Primary or authoritative reference

Nass et al.: MK-677 randomized trial in older adults

Human randomized trial; ibutamoren is not sermorelin.

Primary or authoritative reference

WADA: 2026 Prohibited List

Sermorelin named under S2.2.4; rules are sport- and year-specific.

Primary or authoritative reference

HRSA Poison Help: What you can do

US poison-help contact; suspected overdose requires individual assessment.

Primary or authoritative reference

National Institute on Aging: Aging and alcohol

General older-adult guidance, not a sermorelin interaction trial.

Primary or authoritative reference

National Institute on Aging: Taking medicines safely

General medication handling and communication guidance.

Primary or authoritative reference

American Academy of Dermatology: Hair loss diagnosis and treatment

Cause-specific evaluation; not evidence of sermorelin efficacy.

Primary or authoritative reference

Endocrine Society: Growth and short stature

Pediatric assessment and growth biology; not an adult height-enhancement indication.

Primary or authoritative reference

Hims: Does sermorelin increase testosterone?

Educational page; does not establish current product availability.

Primary or authoritative reference

Empower Pharmacy: Sermorelin acetate injection

Pharmacy product page; not a complete care package or checkout quote.

Primary or authoritative reference

Grant et al.: NAD+ infusion metabolome pilot study

Small IV metabolism study; not proof of anti-aging outcomes or another route.

Primary or authoritative reference

FDA: Ingredients suitable for sterile compounding

NAD+ quality warning; not a claim that every product is contaminated.

Primary or authoritative reference

bmiMD help center: Programs offered

Official program listing; current pricing and terms need confirmation.

Drug developer primary source

Lilly: What to know about retatrutide

Checked September 20, 2026; retatrutide remains investigational and is available through clinical trials.

Provider product page

Maximus: Growth hormone peptides

Contains multiple peptide options; prices depend on selected product, dose, state and term. Clinical claims are marketing, not independent comparisons.

Provider help center

Maximus: Sermorelin protocol overview

Sermorelin-specific administration and care information; not independent outcome evidence.

Provider help center

Maximus: Sermorelin prescriptions, refills and shipping

Explains clinician review, pharmacy fulfillment and support roles; not a tested service guarantee.

US regulator / historical enforcement record

FDA: Empower Pharmacy warning letter, April 2, 2025

Facility-specific warning letter following a 2024 inspection. Not a finding about every current sermorelin vial; current corrective-action status was not independently established.

NIH patient education

NIDDK: Hypothyroidism

Symptoms, diagnosis and established thyroid treatment; not a sermorelin trial.

NIH patient education

NIDDK: Acromegaly

Explains effects of pathological GH excess; does not estimate diabetes risk from prescribed sermorelin.

US regulator

FDA: Drug interactions, what you should know

General medicine, food and supplement interaction principles, not an exhaustive sermorelin interaction list.

US regulator

FDA: Managing the benefits and risks of medicines

General questions for evaluating benefit, follow-up and new medicines.

US regulator

FDA: Safe drug use after a natural disaster

General temperature-exposure guidance. Does not establish a sermorelin stability window or injectable reconstitution method.

US tax authority

IRS: Publication 502, Medical and Dental Expenses

Medical-expense definitions; not an individual insurance or account-eligibility determination.

US tax authority

IRS: Publication 969, Health Savings Accounts and Other Tax-Favored Health Plans

HSA/FSA qualified-expense and recordkeeping rules. Current accessible edition is for 2025; no 2026 numerical limits are inferred.

NIH patient education

MedlinePlus: Anaphylaxis

General emergency allergy recognition; not a sermorelin-specific event rate.

US public health agency

CDC: About cellulitis

Skin infection symptoms and when prompt medical attention is needed.

Human randomized controlled study

Baker et al.: GHRH and cognitive function, controlled trial (2012)

152 enrolled adults; 20 weeks of tesamorelin, not sermorelin. Cognitive outcomes are not dementia prevention.

Human placebo-controlled pilot study

GHRH, cognition and brain connectivity: pilot trial (2026)

22 participants and ten weeks of tesamorelin. No significant direct changes in study measures; exploratory analyses do not establish clinical benefit.

Provider primary source

Gimme Care: public treatment prices

The homepage has sermorelin-specific price rows alongside GLP-1 information. General GLP-1 terms are not automatically sermorelin terms.

Provider product page

Gimme Care: Sermorelin injection

Product-specific offering; not independent evidence of results or a verified checkout.

Provider policy

Gimme Care: Refund policy

Published cancellation and damaged-product procedures, not a universal legal entitlement or tested refund.

Provider product page

Good Life Meds: Sermorelin

Retrieved promotional prices and conflicting stock labels require checkout confirmation; testimonials include other products.

Provider safety page

Good Life Meds: Sermorelin safety information

Provider instructions and warnings; exact pharmacy label and clinician directions remain controlling.

Provider product overview

Lavender Sky Health: Sermorelin

Several routes and formulations; not evidence of equivalence across them.

Provider price list

Lavender Sky Health: Treatment plan pricing

Lists quantities and pharmacy-specific prices; not universal monthly rates or a complete care quote.

Provider service page

Lavender Sky Health: Service pricing

Medical service charges must be distinguished from medication charges.

Provider patient resources

Lavender Sky Health: Prescription summaries

Identifies pharmacy and formulation options; exact prescription and current access need confirmation.

Provider program page

LifeMD: Men’s health program

Contains a sermorelin compounded-product disclosure. Product card and safety text differ on route; no complete sermorelin quote verified.

Professional medical organization

American Heart Association: Home blood pressure monitoring

General measurement and urgent-response guidance; not a sermorelin trial or an individual blood pressure target.

NIH patient education

MedlinePlus: Headache

General headache warning signs and assessment, not a sermorelin-specific risk estimate.

NIH patient education

MedlinePlus: Joint swelling

Unexplained joint swelling and fever require clinical attention; does not diagnose drug causation.

NIH patient education

NIAMS: Carpal tunnel syndrome

Explains nerve compression symptoms; not a finding that sermorelin caused a reader’s symptoms.

NIH patient education

NHLBI: Sleep apnea symptoms

Sleep-related breathing symptoms and evaluation.

NIH patient education

NHLBI: Sleep apnea treatment

Established treatment options; not evidence for sermorelin as an apnea treatment.

US government drug information

DEA: Steroids drug fact sheet

Anabolic steroid classification; separate from peptide identity and sporting rules.

US government patient education

Office on Women’s Health: Menopause treatment

Supports symptom-specific menopause care and distinguishes estrogen/progesterone therapy from other hormone pathways. No drug-specific dosing or individual eligibility is inferred.

Public health pharmacy guidance

NHS Specialist Pharmacy Service: Missed or delayed medicine doses

General advice to seek product-specific instructions and avoid doubling a missed dose; not a sermorelin-specific catch-up schedule.

US public health agency

CDC: Signs and symptoms of stroke

Emergency recognition and calling 911; does not establish a sermorelin-related stroke risk.